Bcal Diagnostics (ASX:BDX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Bcal Diagnostics (ASX:BDX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
BCAL Seeks Board Change at Genetic Signatures
Investor Presentation September 2026
Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report to shareholders
BCAL Diagnostics reports FY2026 loss, advances cancer detection tests, secures funding and leadership changes
BCAL Takes Interest in Genetic Signatures to 18.46%
BCAL Increases Stake in Genetic Signatures to 18.46% to Expand Diagnostic Platform
Notification regarding unquoted securities - BDX
Notification regarding unquoted securities - BDX
Proposed issue of securities - BDX
BCAL Secures Funding for FY2027 Update
BCAL Diagnostics updates on $10 million Convertible Note Facility and funding status
Bioshares Conference Investor Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
BCAL Diagnostics advances cancer detection tests, secures funding, and invests strategically
Notification regarding unquoted securities - BDX
Notification regarding unquoted securities - BDX
Notification regarding unquoted securities - BDX
Notification regarding unquoted securities - BDX
BCAL to Acquire Shares in Genetic Signatures
BCAL acquires 10.2% stake in Genetic Signatures to expand diagnostics portfolio
BCAL Secures Funding for FY2027
BCAL Diagnostics secures $4.9 million funding and $1.4 million R&D tax offset for FY2027
BCAL Develops New Blood Test for Breast Cancer Recurrence
BCAL develops blood test BREASTEST Monitor for detecting local breast cancer recurrence
